Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best growth stocks to invest in for the next 5 years. On Monday, the ...

The field of cytokine biology has seen significant advancements, particularly concerning Interleukin-5 (IL-5) and its role in eosinophil-related disorders.

GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...

Labeling for the interleukin-5 (IL-5) antagonist stipulates use as an add-on maintenance treatment for patients with an eosinophilic phenotype, characterized by a blood eosinophil count of 150 ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) with an ...

Gluten-stimulated interleukin-2 (IL-2) secretion is useful for diagnosis of celiac disease (CeD), according to a study ...

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...

Cite this: Tocilizumab: The First Interleukin-6-Receptor Inhibitor - Medscape - Aug 01, 2008. Abstract and Introduction; IL-6 in RA Pathogenesis; IL-6R Complex; Pharmacology; Pharmacokinetics; ...

Now approved for its fifth indication, mepolizumab, a monoclonal antibody that targets interleukin-5, is indicated as an add-on maintenance treatment for adults with inadequately controlled COPD ...

First approved in 2015 for severe asthma with an eosinophilic phenotype in the US, mepolizumab is a monoclonal antibody that targets and binds to interleukin-5 (IL-5), a key messenger protein ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.